Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis

BACKGROUND: Two phase III trials of photodynamic therapy (PDT) with BF-200 ALA, a recently approved nanoemulsion formulation of 5-aminolaevulinic acid (ALA) demonstrated high clearance rates in mild-to-moderate actinic keratosis (AK). The comparison to a registered methyl aminolaevulinate (MAL) crea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirschka, T, Radny, P, Dominicus, R, Mensing, H, Brüning, H, Jenne, L, Karl, L, Sebastian, M, Oster-Schmidt, C, Klövekorn, W, Reinhold, U, Tanner, M, Gröne, D, Deichmann, M, Simon, M, Hübinger, F, Hofbauer, G, Krähn-Senftleben, G, Borrosch, F, Reich, K, Berking, C, Wolf, P, Lehmann, P, Moers-Carpi, M, Hönigsmann, H, Wernicke-Panten, K, Hahn, S, Pabst, G, Voss, D, Foguet, M, Schmitz, B, Lübbert, H, Szeimies, R-M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660784/
https://www.ncbi.nlm.nih.gov/pubmed/23252768
http://dx.doi.org/10.1111/bjd.12158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660784/
https://www.ncbi.nlm.nih.gov/pubmed/23252768
http://dx.doi.org/10.1111/bjd.12158

Ejemplares similares